For citations:
Rudakova A.V., Stadnik E.A. Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment. Oncohematology. 2020;15(1):73-82. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-1-73-82
Fullscreen
Popular articles
Vol 12, No 4 (2017)
Vol 9, No 4 (2014)
Vol 11, No 2 (2016)
Vol 12, No 3 (2017)
Vol 15, No 2 (2020)
Article Tools
Email this article (Login required)
Email the author (Login required)
Email this article (Login required)
Email the author (Login required)
About the Authors
Keywords
Hodgkin lymphoma
Hodgkin’s lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia
anemia
bortezomib
chemotherapy
children
chronic lymphocytic leukemia
chronic myeloid leukemia
diffuse large B-cell lymphoma
flow cytometry
hematopoietic stem cell transplantation
lymphoma
minimal residual disease
multiple myeloma
oncology
relapse
rituximab
toxicity
treatment
“ABV-press” publishing house
Research Institute of Carcinogenesis
Floor 3, 24 Kashirskoe Shosse, Build. 15,
Moscow 115478, Russian Federation
tel. +7 (499) 929-96-19,
E-mail: abv@abvpress.ru
